ENHERTU® approved in the U.S. for the treatment of patients with previously treated HER2 positive advanced gastric cancer
First HER2 directed medicine approved for patients with gastric cancer in a decade TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of